Receipt of hormone therapy is lacking among Black men with prostate cancer
Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Multidisciplinary Care for Patients With mCRPC
In the third article of this series, Paul E. Dato, MD, provides comprehensive insights on the multidisciplinary care of patients with metastatic castration-resistant prostate cancer.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
MRI-guided TULSA effective for managing localized prostate cancer
“Our experience with TULSA demonstrates substantial post-procedure decreases in PSA level, PSA density, and prostate volume,” the researchers wrote.
Small mpMRI index lesions are favorable marker for guiding active surveillance strategies
Small index lesions on initial multiparametric MRI were linked to a less aggressive clinical course for patients with prostate cancer on active surveillance.
2 Clarke Drive Cranbury, NJ 08512